Acrodermatitis continua of Hallopeau response to optimized biological therapy.

Abstract

Acrodermatitis continua of Hallopeau, first described in 1890, is an uncommon variant of pustular psoriasis. It presents as a sterile pustular eruption of the tips of fingers and toes. The condition has a chronic, relapsing course and is often resistant to many anti-psoriatic therapies. In the following case, we present our experience of etanercept use in a 61-year-old man. Although initial therapy with high-dose etanercept achieved a rapid, sustained response and remission, the lesions relapsed a few months into a lower, maintenance dosage. This result prompted the use a second biotherapeutic agent ustekinumab, which resulted in complete remission, but required a higher dosage than recommended with reduced dosing intervals.

• Authors: Alanoud Adas, Ali Dadban, Jean-Philippe Arnault, Guillaume Chaby, Catherine Lok
• Journal: Dermatology online journal (Dermatol Online J) Vol. 25 Issue 2 (Feb 15 2019) ISSN: 1087-2108 [Electronic] United States
• PMID: 30865417 (Publication Type: Case Reports, Journal Article)

Chemical References

• Biological Products
• Dermatologic Agents
• Ustekinumab
• Etanercept

Topics

• Acrodermatitis (drug therapy, etiology)
• Biological Products (therapeutic use)
• Dermatologic Agents (administration & dosage, therapeutic use)
• Etanercept (administration & dosage, therapeutic use)
• Humans
• Male
• Middle Aged
• Psoriasis (complications, drug therapy)
• Recurrence
• Ustekinumab (administration & dosage, therapeutic use)